Wordt geladen...
Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of end-stage kidney failure. At present, only one drug, tolvaptan, has been approved for use to slow disease progression, but its use is limited by reduced tolerability and idiosyncratic liver toxicity. Thiazolid...
Bewaard in:
| Gepubliceerd in: | Clin Kidney J |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Oxford University Press
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8243263/ https://ncbi.nlm.nih.gov/pubmed/34221378 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfab062 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|